Latest Conference Articles

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

After reviewing the evidence, nurses switched from heparin-based flushes to all saline flushes for patients disconnecting chemotherapy at home.

An oncology nurse explains how her institution created a surgical path card that improved wait times and patient satisfaction in adults undergoing cancer surgery.

The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.

The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost savings from less drug waste.

The newly appointed president of the Oncology Nursing Society (ONS) discussed healthcare policies that she and ONS will continue to advocate for in the cancer space.

Poor sleep quality among those with lung cancer and COPD emphasize the need to develop effective assessment strategies.

A pilot study proved that a nurse-coordinated approach shows promise in treating more than just 1 symptom among patients with cancer.

Advanced practice providers can lead clinical teams and patients to boost oncology clinical trial enrollment, a nurse practitioner explained.

A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.

As symptom severity can vary by patient, it is key for nurses to increase assessment for early intervention of patients with head and neck cancer following treatment, according to Meredith Cummings, PhD(c), BSN, RN, OCN.

Establishing a nurse-led system to administer tocilizumab in patients receiving bispecific antibodies tended to get the immunosuppressive drug to patients faster.

A feasibility study on the use of a mobile application for patients after undergoing a stem cell transplant may help care teams quickly identify and treat graft-versus-host disease.

Patients who were given telehealth, vs in-person, exercise programs to manage their symptoms from cancer care experienced similar outcomes, highlighting an alternative for providers to consider.

Results from the CARTITUDE-2 trial support cilta-cel in patients with multiple myeloma, which addresses the unmet needs of these patients, an expert presented.

An oncology nurse details strategies used at his institution to reduce burnout — which can ultimately decrease the rate of “silent quitting.”

Encouraging responses were observed in most patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab.

Patients in the CARTITUDE-4 trial experienced a high response rate to the treatment as early as their first relapse.

The establishment of a multidisciplinary committee can help identify opportunities to best face the ongoing cancer drug shortage.

Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Patients with gastric/GEJ adenocarcinoma treated with cadonilimab plus oxaliplatin and capecitabine obtained a survival benefit regardless of PD-L1 expression.

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.